Gabapentin
Product Images NDC 67296-1721

This is a dosage table outlining the suggested total daily dose range of the medication Gabapentin based on different levels of renal function measured by creatinine clearance. It includes dose regimens for patients with different creatinine clearance levels and outlines supplemental post-hemodialysis doses for patients on hemodialysis. The table also suggests how to adjust the daily dose of the medication for patients with creatinine clearance below 15 mL/min. Finally, it provides an equation to estimate creatinine clearance based on age, weight, and serum creatinine levels.*

This is a table presenting the risks associated with antiepileptic drugs categorized by indication (epilepsy, psychiatric, and other). The table displays the number of placebo patients and drug patients with events per 1000 patients, relative risk (incidence of events in drug patients compared to placebo patients), and risk difference (additional drug patients with events per 1000 patients).*

This is a table presenting the adverse effects of Gabapentin compared to Placebo in patients with Postherpetic Neuralgia. The table shows the percentage of patients who reported various symptoms under "Body as a Whole", "Digestive System", "Metabolic and Nutritional Disorders", "Nervous System", "Respiratory System", and "Special Senses". Some of the adverse reactions reported were asthenia, infection, diarrhea, dry mouth, dizziness, somnolence, and blurred vision.*

This is a table showing the adverse reactions in pooled placebo-controlled add-on trials in epilepsy patients over 12 years of age who were treated with Gabapentin and Placebo. The table displays the percentage of adverse reactions experienced by patients in each group. The adverse reactions are listed under various body systems, such as body as a whole, cardiovascular, digestive system, nervous system, respiratory system, skin and appendages, urogenital system, and special senses. The adverse reactions for each group include fatigue, increased weight, back pain, peripheral edema, vasodilation, dyspepsia, dry mouth or throat, constipation, dental abnormalities, somnolence, dizziness, ataxia, nystagmus, tremor, dysarthria, amnesia, depression, abnormal thinking, abnormal coordination, pharyngitis, coughing, abrasion, impotence, diplopia, and amblyopia. Amblyopia is described as blurred vision.*

This is a table presenting the adverse reactions observed in a placebo-controlled add-on trial conducted on pediatric epilepsy patients aged between 3 to 12 years who were administered Gabapentin®. The table presents the number and percentage of adverse reactions observed in the Gabapentin group compared to the placebo group. Adverse reactions reported by the Gabapentin group include increased weight, fatigue, nausea and/or vomiting, somnolence, hostility, emotional lability, dizziness, hyperkinesia, bronchitis, and respiratory infection. The adverse reactions observed in the placebo group were fever and body rash. The table specifies that the patients were also receiving other antiepileptic therapy concurrently.*

This is a table showing the duration, dosages, and number of patients in two controlled studies using Gabapentin to treat PHN (post-herpetic neuralgia). The first study lasted 8 weeks and used a dosage of 3,600 mg/day. There were 113 patients receiving Gabapentin and 116 receiving a placebo. The second study lasted 7 weeks and used dosages of either 1,800 mg/day or 2,400 mg/day. There were 223 patients receiving Gabapentin and 111 receiving a placebo. The total number of patients in both studies was 563, with 336 receiving Gabapentin and 227 receiving a placebo. The medication was given in three divided doses per day.*

The text is a figure caption showing the success rate of pain reduction in different studies related to Controlled PHN. It also includes statistical significance value (p<0.001) for one of the studies. There are some unclear characters and symbols that may have been misread by . The last line appears to contain medication dosage information.*

NDC: 67296-1721-3 is a medication called gabapentin, which is only available through a prescription. This particular package includes 30 capsules with each containing 100mg of gabapentin. The lot number for this package is 901936X1, and it has an expiration date of 04/21. The usual adult dosage should be seen on the package insert. The medication should be stored at a controlled room temperature of 20-25C (68-77F). The distributor of the medication is Redpharm Drug located in Eden Prairie, MN 55344.*